Industry News
Mini-engines set to replace batteries
Engineers have developed tiny engines - only a few millimetres wide - that will soon replace a standard battery.
[ + ]Bionomics upbeat despite bigger annual loss
Adelaide epilepsy specialist Bionomics (ASX:BNO) has reported an after-tax loss of $4.54 million for the year to June 30, up from $3.49 million in 2001-02. [ + ]
Monash launches new brain research centre
Monash University yesterday launched its new Centre for Brain and Behaviour, bringing together more than 150 researchers including students and postdocs from 21 university departments and research centres. [ + ]
Vic opposition claims synchrotron cost blow-out
Political sparring over the Australian National Synchrotron raised its head again last week, when Victoria's opposition deputy leader Phil Honeywood claimed that the project would cost the state AUD$537 million over the next decade, and called the project a white elephant. [ + ]
More biotechs join S&P300 index
Market analyst Standard and Poor's has added four more Australian biotechnology firms and a medical device company to its S&P300 index. [ + ]
Xcell collaborators earn $1m NIH grant
Collaborators of Perth devices company Xcell Diagnostics (ASX:XEL) have received a US NIH grant worth more than AUD$1 million (US$702,000) to perform clinical studies on Xcell's Funhaler paediatric asthma spacer device. [ + ]
Researchers get a preview of synchrotron-based medical opportunities
More than 130 scientists and clinicians got a glimpse of synchrotron-based medicine at a recent workshop held at the Peter MacCallum Cancer Centre in Melbourne. [ + ]
Eiffel signs US insulin trial deal
Melbourne drug re-engineering company Eiffel Technologies (ASX:EIF) has signed an agreement with a large US drug-delivery company to trial an inhalable form of insulin produced by Eiffel's proprietary supercritical fluid technology. [ + ]
Worldwide recognition for researcher’s foresight
International honours have been bestowed on Charles Sturt University (CSU) Professor of Irrigation Graeme Batten for his leading research into the rapid, reliable and low cost analysis technique which has revolutionised crop management.
[ + ]Cerylid regroups, lays off staff
Unlisted Melbourne company Cerylid Biosciences has reorganised, necessitating the layoff of a portion of its staff. [ + ]
Feds let CSL supply deal lapse
The federal government made a decision more than a year ago not to take up an option to extend its contract with CSL for the supply of blood plasma products to Australian hospitals for another five years. [ + ]
Biotron adds dengue virus to discovery roster
Canberra biotechnology company Biotron (ASX: BIT) has added dengue virus to the lengthening list of potentially lethal human viruses that possess ion-channel genes. [ + ]
UK hints at end to drug price controls
The British government said it might be possible to relax or abolish price and profit controls on branded prescription medicines in the UK. [ + ]
Agenix appoints new US vet distributor
Brisbane-based Agenix (ASX:AGX) has appointed a new distributor for its animal health diagnostic products in the US. [ + ]
Arthritis CRC picks up new funding and partners
The Cooperative Research Centre for Chronic Inflammatory Diseases has received AUD$5 million in supplementary funding from the federal government to implement two new programs. [ + ]